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Catheter ablation of atrial fibrillation in 
patients with left ventricular dysfunction
antonis M. sideris, loukas K. pappas
A B S T R A C T
there is a complex interplay between atrial fibrillation and congestive heart failure. 
these two clinical entities often coexist, resulting in significant morbidity, affecting 
prognosis and rendering their management even more challenging. new nonphar-
macologic therapies are emerging and may alter the management of these patients. 
among them, catheter ablation of atrial fibrillation seems to be a promising thera-
peutic approach as it leads to improvement of cardiac function, symptoms, exercise 
capacity, and quality of life. this article reviews the role of catheter ablation in con-
temporary management of atrial fibrillation among patients with left ventricular dys-
function.
I N T R O D U C T I O N
atrial fibrillation (af) is the most common arrhythmia encountered in clinical 
practice and it is responsible for substantial morbidity and mortality [1,2]. it occurs 
very often in patients with congestive heart failure (Chf) and the prevalence increases 
with the severity of the disease. af is present in about 10% of patients in new york 
heart association (nyha) functional class i, and up to 0% in patients with more 
advanced disease [3,4]. these two conditions seem to be linked together, and Chf 
may either be the cause or the consequence of af []. an increase in the prevalence 
of these two clinical entities is occurring in part because of the demographic shift 
toward an ageing population [6,7].
despite the clinical implications of af in Chf, the reasons for its high prevalence 
are poorly understood. in a recent elegant study, sanders et al. addressed the reason 
for the higher prevalence of af in patients with Chf. patients with Chf exhibited 
atrial remodelling characterized by anatomic and structural changes including, atrial 
enlargement, increased refractoriness and sinus node dysfunction, abnormalities 
of conduction, a greater number and duration of double potentials associated with 
areas of low voltage and electrical silence. these abnormalities were associated with 
an increased inducibility and sustainability of af and may be responsible in part for 
the increased incidence of atrial arrhythmias in patients with Chf [8]. once af has 
started, it may worsen Chf because of faster heart rate with shortened filling time, 
absence of atrial contribution to cardiac output, and irregularity of the ventricular 
rhythm, leading to further hemodynamic deterioration [9]. atrial dilation also plays an 
important role in the occurrence af [10]. a recent subanalysis of the raCe study is 
consistent with these findings, suggesting partial reversibility of atrial and ventricular 
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anatomical and functional characteristics after prolonged 
af periods. rhythm control was associated with a signifi-
cant reduction of left atrial size, especially if sinus rhythm 
was maintained. improvement of left ventricular fractional 
shortening was significant only in the case of maintenance of 
sinus rhythm [11].
the independent impact of af on the prognosis of Chf 
patients has been examined in several studies but remains a 
subject of controversy. however, a plethora of epidemiologi-
cal surveys and large clinical trials in Chf provides strong 
evidence that af is a marker of increased mortality [12-16].
R H y T H M  C O N T R O L  
V E R S U S  R A T E  C O N T R O L
based on its pathophysiological and epidemiological 
background, it had long been believed that rhythm control 
for af, was the preferable type of management, however the 
results of recent randomized controlled trials have cast doubt 
on whether rhythm control should be routinely applied in 
patients with af [17-21]. all of these trials should be limited 
in the application of their results to the entire af patient 
population. the subset of patients with af and Chf was 
underrepresented (<9% of patients) in the largest of these 
trials (affirM). a subgroup analysis of affirM, revealed 
a benefit conferred by rhythm control in patients with Chf 
or left ventricular (lv) dysfunction, which was a prespecified 
subgroup in affirM. furthermore, the “on-treatment” 
analysis of affirM showed that presence of sinus rhythm 
predicted a considerably lower risk of death [22]. Moreover, 
a substudy of the raCe trial reported a survival benefit in 
Chf patients who were able to maintain sinus rhythm. Chf 
patients assigned to the rhythm-control group who main-
tained in sinus rhythm throughout the study demonstrated 
a cardiovascular mortality rate of 0%, compared with 9.% 
in patients who reverted back to af. Mortality benefits were 
also observed in the diaMond study in Chf patients 
who maintained sinus rhythm on the antiarrhythmic drug 
dofetilide [23,24]. however, fewer than 0% of patients on 
an antiarrhythmic regimen remained in sinus rhythm at the 
end of 1 year [2]. these trials also did not include patients 
with highly symptomatic af who might not be candidates for 
rate control. in particular, patients with diminished diastolic 
compliance (for example, long-standing hypertension and 
hypertrophic cardiomyopathy) may not tolerate loss of atrial 
function and benefit immensely from maintenance of sinus 
rhythm [26,27]. the question of rate versus rhythm strategy 
in patients with Chf remains unanswered and is currently 
being addressed in the atrial fibrillation and Congestive 
heart failure (af-Chf) trial [28].
A B L A T E  A N D  P A C E  T H E R A P y
inadequate rate control is associated with the develop-
ment of tachycardia-induced cardiomyopathy [29]. atrioven-
tricular (av) junction ablation with pacing is indicated for 
patients who cannot achieve adequate rate control with av 
nodal blocking drugs or do not tolerate the doses of these 
medications that are required for adequate rate control. a 
meta-analysis of 21 mostly nonrandomized studies, including 
1181 patients, showed a uniform improvement of quality of 
life and of health care utilization with ablation and pacing in 
patients with refractory atrial tachyarrhythmias [30]. these 
results were confirmed in randomized studies in patients 
with permanent, as well as paroxysmal af [31,32]. however, 
av junction ablation creates dependence on an implanted 
pacemaker. there is also a finite risk of sudden death due to 
torsade de pointes or ventricular fibrillation [33]. furthermore, 
recent data suggest that mandatory right ventricular pacing 
may sometimes result in impaired ventricular function and 
Chf [34,3]. this was also highlighted in the dual Chamber 
and vvi implantable defibrillator (david) trial in patients 
with underlying left ventricular (lv) dysfunction (lv ejec-
tion fraction [ef] 40%), in which rv pacing increased the 
risk of death or heart failure hospitalization [36]. of note, in 
3 recent prospective, randomized trials of ablate and pace 
therapy, the lvef following av node ablation showed only 
a modest improvement or no change in patients with lv 
dysfunction prior to the procedure [37-39]. data from the 
left ventricular-based Cardiac stimulation post av nodal 
ablation evaluation (pave) showed that biventricular pacing 
is the preferred modality of pacing in patients undergoing av 
node ablation and pacemaker implantation [40].
C A T H E T E R  A B L A T I O N  O F  A F
in theory, a therapy that restores and maintains sinus 
rhythm while avoiding the adverse effects of antiarrhythmic 
drugs would improve survival. one such therapy is catheter 
ablation to eliminate af. in contrast to antiarrhythmic (aad) 
drug therapy, catheter ablation seems to have minimal long-
term cumulative risk after the periprocedure period.
 since the pivotal role of the pulmonary veins (pv) in 
the genesis of af was first discovered by haissaguerre et 
al. several pv-based catheter ablation strategies have been 
developed. Currently, the techniques used for ablation of af 
include one or a combination of the following techniques: 
isolation of the pvs (segmental or circumferential approach) 
with or without demonstration of pulmonary vein left atrial 
conduction block, left atrial linear ablation (mitral isthmus, 
roof, and posterior wall), ablation of the complex fractionated 
electrograms, and ablation of the autonomic ganglions [41-44]. 
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these procedures either use a circular mapping catheter under 
fluoroscopic guidance to electrically isolate the pvs from the 
left atrium or create radiofrequency lesions encircling the pvs 
under the guidance of a three-dimensional electroanatomic 
mapping system [4-47]. the aim of catheter ablation is to 
“cure” af, but much of the available data have come from 
small studies with relatively short periods of follow-up. based 
on these data, success rates range from about 60-90% and were 
improved to a varying degree by the use of aads. a second 
procedure was necessary in 20-30% of patients. success rates 
for persistent or permanent af or in patients with markedly 
dilated atria are lower [48-8].
in the largest of these trials pappone and his colleagues 
analyzed the impact of catheter ablation of af compared with 
drug therapy for sinus rhythm maintenance [9]. the study 
was prospective but not randomized and included a relatively 
diverse patient population with prevalent structural heart 
disease. ablation therapy was associated with reductions in 
the risk of death (4%), major adverse events (%), and recur-
rence of af (70%). of note, they reported that maintenance 
of sinus rhythm as a time-dependent variable also reduced 
the risk of death and adverse events regardless of treatment 
strategy. the results reported in this study contradict the 
conclusions drawn by the rate versus rhythm control trials 
[60]. in a large worldwide survey of centers performing af 
ablation, 2% of patients who were not taking antiarrhythmic 
medications were asymptomatic, and another 24% were suc-
cessfully treated with antiarrhythmic medications after abla-
tion [61]. in addition, there was a high rate of maintenance of 
sinus rhythm among those patients who underwent a repeat 
procedure. the overall incidence of major complications was 
6% [62]. very recently, some investigators have reported that 
catheter-based af ablation seems to be more effective than 
aads for the treatment of paroxysmal and permanent af. 
wazni et al showed that pulmonary vein isolation as first-
line therapy in patients with symptomatic af was associated 
with improved clinical outcomes compared with initial aad 
therapy [63]. the Catheter ablation for the Cure of atrial 
fibrillation (CaCaf) trial was an open, prospective, rand-
omized, multicenter study which demonstrated that patients 
with treatment-resistant paroxysmal or persistent af who were 
treated with a single session of catheter ablation therapy in 
combination with aads were significantly less likely to experi-
ence recurrence of af than patients treated with aads alone. 
importantly, investigators found that the long-term efficacy of 
ablation therapy was independent of drug therapy [64]. oral 
et al reported that ablation was superior to amiodarone for 
the maintenance of sinus rhythm in patients with persistent 
af [6]. ablation for paroxysmal atrial fibrillation (apaf) 
trial, which randomized patients to aads or pulmonary vein 
ablation, showed a marked difference in freedom from recur-
rent arrhythmia in favor of the ablation group [66]. however, 
catheter-based af ablation is a relatively new technique, and 
while the studies report high success rates from high-volume 
centers, most centers currently have limited experience. ad-
ditionally, the long-term follow-up of patients after ablation 
is limited, and given the natural history of af, it is quite 
possible that the long-term success rates of this procedure 
will taper off significantly. furthermore, these studies did 
not focus on patients with structural heart disease although 
the majority has included some proportion of patients with 
structural heart disease.
C A T H E T E R  A B L A T I O N  O F  A F  I N  T H E  S E T T I N g 
O F  LV  D y S F U N C T I O N
a central question in treating patients with af and conges-
tive heart failure (Chf) is whether maintaining normal sinus 
rhythm per se affects mortality, morbidity or quality of life. 
recent evidence from the affirM investigators, in addition 
to confirming the adverse prognostic effects of congestive 
heart failure, highlights the potential benefit of maintaining 
sinus rhythm if it could be achieved without the adverse effects 
of antiarrhythmic drugs [67]. there is preliminary evidence to 
support that catheter ablation may become a routine clinical 
approach to af in patients with heart failure. there have been 
three published studies and several abstracts so far addressing 
this issue (table 1) [68-73]. the outcomes of catheter ablation 
in patients with lv dysfunction were impressive. there was 
a consistent improvement in lvef in these patients, which 
in the majority of studies reached statistical significance and 
although the af recurrence rate in impaired lvef patients 
was higher than in normal lvef subjects, a significant per-
centage of patients with lv dysfunction remained af-free. 
in a nonrandomized study Chen et al examined the effect of 
catheter ablation of af in patients with lv dysfunction. the 
study included 377 consecutive patients over a 19-month pe-
riod, a control group of 283 patients was compared with a study 
group of 94 patients with an lvef below 40%. patients were 
selected on the basis of the presence of symptoms and drug 
resistance. Circumferential ostial mapping and radiofrequency 
“cooled tip” ablation for pv isolation was “classically” guided 
TABLE 1. trials of af in heart failure
n Success rate Increase 
in EF
p
Chen [69] 94 96% 36±7 41±6 0.1
hsu [68] 8 78% (on aad) 3±7 6±13 0.001
pappone [71] 9 81% (on aad) 31±9 44±6 <0.0
Gentlesk [73] 3 90% (on aad) 42±8 7±8 <0.01
Cha [72] 19 68% (on aad) 34±6 1±7 0.003
tondo [70] 40 87% (on aad) 332 473 <0.01
abbreviations: aad: antiarrhythmic drugs, increase in ef: values pre, 
post-ablation
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by angiography in the first 6 patients and by intracardiac ul-
trasound in the last 321. the latter allowed for monitoring of 
tissue overheating and impending impedance rise. a minority 
of patients underwent associated cavotricuspid isthmus abla-
tion, but no additional linear lines were performed. overall, 
the excellent results of this series fit with the best-published 
data on pv ablation techniques. of note patients with im-
paired lvef had a significantly worse outcome compared 
with controls after a first procedure but identical outcome 
after the second procedure. these results were obtained 
without significantly greater complications, although there 
was a trend toward a higher rate of cerebrovascular accident 
in the low lvef group. pulmonary vein ostial size measured 
by intracardiac echocardiogram was significantly larger in 
low lvef patients than in those with normal lv function. 
there was a nonsignificant (%) increase in lvef after abla-
tion. however, using the short form-36 Questionnaire, both 
normal and low-lvef patients experienced a clear improve-
ment in quality of life [69]. in a prospective non-randomized 
study hsu et al evaluated 8 consecutive patients with Chf 
and a lvef of less than 4% who were undergoing catheter 
ablation for af and compared them with 8 patients without 
Chf who were undergoing ablation for af, matched for age, 
sex, and classification of af. the investigators evaluated 8 
consecutive patients with Chf and a lvef of less than 4% 
who were undergoing catheter ablation for af and compared 
them with 8 patients without Chf who were undergoing 
ablation for af, matched for age, sex, and classification of 
atrial fibrillation. after a mean of 12±7 months, sinus rhythm 
was maintained in 78% of the patients with Chf and in 84% 
of the controls (p= .34). sinus rhythm persisted without use 
of aads in 69% and 71% of patients, respectively. in the 
group with Chf, there were improvements in exercise ca-
pacity, symptoms, quality of life, lvef (lvef increased by 
21%±13% and fractional shortening increased by 11%±7%; 
p<.001 for both comparisons), and left ventricular dimen-
sions (diastolic diameter decreased by 6±6 mm; p=.03; and 
systolic diameter decreased by 8±7 mm; p<.001). the lvef 
improved significantly not only in patients without concurrent 
structural heart disease (24±10 percent, p<0.001) and those 
with inadequate rate control before ablation (23±10 percent, 
p<0.001), but also in those with coexisting heart disease 
(16±14 percent, p<0.001) and adequate rate control before 
ablation (17±1 percent, p<0.001). the striking improvement 
in lv function after restoration of sinus rhythm in 92% of the 
patients who had inadequate rate control without coexisting 
heart disease suggests that Chf was attributable primarily to 
tachycardia-mediated cardiomyopathy in this group of patients 
[68]. further evidence for the role of catheter ablation of af 
in patients with left ventricular dysfunction has been demon-
strated in a recent study by tondo et al [70]. one hundred and 
five consecutive patients who underwent pv vestibule ablation 
for the control of af were studied. the population comprised 
40 patients affected by lv dysfunction with lvef <40% and 
6 patients with normal lv function. after 14±2 months, 87% 
of patients with impaired lv function and 92% of patients 
with normal lv function were in sinus rhythm, with or without 
aads. a significant improvement in lvef and fractional 
shortening was documented in patients with lv dysfunction. 
evaluation of exercise capacity and quality of life documented 
better improvements in patients with impaired lv function 
compared to patients with normal lv function.
Cardiac resynchronization therapy (Crt) with biv-
entricular pacing is an effective therapy in symptomatic, 
drug-refractory Chf patients with prolonged Qrs and low 
lvef. however, Crt may be ineffective in the setting of af 
due to inhibition of resynchronization therapy by the rapid 
intrinsic av nodal conduction. thus, an important issue 
remains whether Crt in patients with chronic af should be 
accompanied by av node ablation. paba Chf study was 
the first randomized trial to directly compare pulmonary vein 
antrum isolation versus av node ablation and biventricular 
pacing in Chf patients with drug-resistant af. pulmonary 
vein isolation improved lvef, 6-minute walk distance, and 
quality of life compared with the use of av node ablation and 
biventricular pacing. it was also demonstrated that patients 
treated with pulmonary vein ablation were significantly more 
likely to be free of af at 6 months than those treated with av 
node ablation and biventricular pacing [74,7].
Catheter ablation in patients with lv dysfunction seems 
FIgURE 1. Circumferential ablation around pulmonary vein os-
tia. shown is a posterior projection of a 3-dimensional replica of 
the left atrium as constructed with an electroanatomic mapping 
system. brown tags represent points at which radiofrequency 
energy was delivered. the left- and right-sided pulmonary veins 
are encircled. the mitral valve isthmus and roof lines are also 
shown.
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